Contineum Therapeutics Inc. announced topline results from its Phase 2 VISTA trial evaluating PIPE-307, an M1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS). The study demonstrated that PIPE-307 had an acceptable safety and tolerability profile at both tested doses. However, the trial did not meet its prespecified primary or secondary efficacy endpoints, with no significant change observed in binocular 2.5% low contrast letter acuity across treatment arms. The company stated that it continues to analyze exploratory endpoints and plans to present the complete dataset at a future medical meeting, with full results to be published in a peer-reviewed medical journal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120828592) on November 20, 2025, and is solely responsible for the information contained therein.